Background-␤-Adrenergic stimulation is the main trigger for cardiac events in type 1 long-QT syndrome (LQT1). We evaluated a possible association between ion channel response to ␤-adrenergic stimulation and clinical response to ␤-blocker therapy according to mutation location. Methods and Results-The study sample comprised 860 patients with genetically confirmed mutations in the KCNQ1 channel. Patients were categorized into carriers of missense mutations located in the cytoplasmic loops (C loops), membrane-spanning domain, C/N terminus, and nonmissense mutations. There were 27 aborted cardiac arrest and 78 sudden cardiac death events from birth through 40 years of age. After multivariable adjustment for clinical factors, the presence of C-loop mutations was associated with the highest risk for aborted cardiac arrest or sudden cardiac death (hazard ratio versus nonmissense mutationsϭ2.75; 95% confidence interval, 1.29 -5.86; Pϭ0.009). ␤-Blocker therapy was associated with a significantly greater reduction in the risk of aborted cardiac arrest or sudden cardiac death among patients with C-loop mutations than among all other patients (hazard ratioϭ0.12; 95% confidence interval, 0.02-0.73; Pϭ0.02; and hazard ratioϭ0.82; 95% confidence interval, 0.31-2.13; Pϭ0.68, respectively; P for interactionϭ0.04). Cellular expression studies showed that membrane spanning and C-loop mutations produced a similar decrease in current, but only C-loop mutations showed a pronounced reduction in channel activation in response to ␤-adrenergic stimulation. Conclusions-Patients with C-loop missense mutations in the KCNQ1 channel exhibit a high risk for life-threatening events and derive a pronounced benefit from treatment with ␤-blockers. Reduced channel activation after sympathetic activation can explain the increased clinical risk and response to therapy in patients with C-loop mutations. (Circulation.
events in patients with LQT1. 2 Activation of ␤1-adrenergic receptors is the major signaling pathway contributing to the increase in heart rate and cardiac output during exercise. ␤1-Adrenergic receptor activation leads to activation of protein kinase A (PKA), which directly phosphorylates the KCNQ1 subunit, increasing I Ks function. 3, 4 The increase in I Ks is thought to suppress the premature beats and afterdepolarization induced by increased L-type Ca 2ϩ currents during ␤-adrenergic stimulation. 5 Accordingly, ␤-blockers have been considered the first-line therapy in LQT1 patients without a history of aborted cardiac arrest (ACA). Data from several prior LQTS studies 1, 6 demonstrate that despite the reduction in the risk of cardiac events with ␤-blocker therapy among LQT1 patients, there is a considerable cardiac residual event rate among patients who are being treated with this mode of medical therapy (Ϸ10 cardiac events per 100 person-years), 6 suggesting that ␤-blockers may be less effective in certain subgroups of LQT1 patients.
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The KCNQ1 protein consists of 676 amino acid residues with an intracellular N-terminus region, 6 membranespanning segments with 2 connecting cytoplasmic loops (C loops), and an intracellular C-terminus region. 7 Prior genotype-phenotype studies have provided important information on the effect of location and coding type of the channel mutations on the phenotypic manifestations and clinical course of LQT1 patients. These studies have shown that missense mutations and mutations located at the transmembrane region (including the C loops) were associated with greater risk for cardiac events. 8 However, the mechanism related to the increased risk associated with transmembrane mutations has not been studied. C loops, part of the transmembrane region, were suggested to affect adrenergic channel regulation by PKA. 9 We therefore hypothesized that the previously reported finding about the risk associated with transmembrane mutations 8 is related to the effect of C-loop mutations within this region. Accordingly, the present study was carried out in a large cohort of subjects having a spectrum of KCNQ1 mutations from the International LQTS Registry and was designed to investigate the clinical outcomes among KCNQ1 mutation carriers by further dividing the transmembrane region into membrane-spanning and C-loop domains, to determine a possible differential response to ␤-blocker therapy depending on mutation location and function related to PKA regulation, and to relate the clinical data to functional studies of changes in I Ks function and ␤-adrenergic receptor regulation in mammalian cells.
Methods

Study Sample
The study comprised 860 patients with genetically confirmed KCNQ1 mutations derived from 170 proband-identified families. The proband in each family had QTc prolongation not resulting from a known secondary cause. The subjects were drawn from the Rochester (nϭ637), the Netherlands (nϭ94), the Japanese (nϭ82), the Danish (nϭ43), and the Swedish (nϭ4) portions of the Multicenter Mutation Registry. All subjects or their guardians provided informed consent for the genetic and clinical studies. Patients with congenital deafness and patients with multiple LQTS-associated mutations were excluded from the study.
Phenotype Characterization
On enrollment, routine clinical and ECG information was obtained from birth to the participants' enrolled age, and ongoing clinical information was obtained at yearly intervals thereafter. For each patient, data on personal and family histories, cardiac events, and therapy were systematically recorded at enrollment and at each visit or medical contact. Clinical data, recorded on prospectively designed forms, included patient and family histories and demographic, ECG, therapeutic, and cardiac event information. Data on ␤-blocker therapy included the starting date and discontinuation date if appropriate. Information on the end point of ACA or sudden cardiac death (SCD) was also verified through requested medical records. Every effort was made to confirm an underlying life-threatening arrhythmia when observed or documented by medical staff.
Genotype Characterization
The KCNQ1 mutations were identified with the use of standard genetic tests performed in academic molecular genetics laboratories. Genetic alterations of the amino acid sequence were characterized by location and by the specific type of mutation (missense, splice site, in-frame insertions/deletions, nonsense, stop codon, and frameshift).
We evaluated the risk associated with 4 main prespecified subgroups: C-or N-terminus missense, membrane-spanning missense, C-loop missense, and nonmissense (ie, splice sites, in-frame insertions, in-frame deletions, stop codons, and frameshift). The membrane-spanning region of the KCNQ1-encoded channel was defined as the coding sequence involving amino acid residues between 124 and 170 (S1-S2), 196 and 241 (S3-S4), and 263 and 355 (S5-S6), with the C-loop region between residues 171 to 195 (S2-S3) and 242 to 262 (S4-S5; Figure 1 ). The N-terminus region was defined before residue 124 and the C-terminus region after residue 355.
To minimize survival bias, we included patients who died before they were genotyped (nϭ64). They were assumed to have the mutation that their first-degree relatives had. All other patients were confirmed through genotyping.
Figure 1.
Frequency and location of mutations in the KCNQ1 potassium channel. Diagrammatic location of 99 different mutations in the KCNQ1 potassium channel involving 860 subjects. The ␣-subunit involves the N-terminus (N), 6 membranespanning segments, 2 cytoplasmic loops (S2-S3 and S4-S5), and the C-terminus portion (C). The size of the circles reflects the number of subjects with mutations at the respective locations.
Cellular Expression Studies
To study the mechanism underlying the risk for cardiac events in patients with missense C-loop mutations, we measured channel function and regulation for channels formed with wild-type (WT) subunits coexpressed with 4 mutant subunits present in C loops (G189R, R190Q, R243C, and V254M) and 4 mutant subunits present in the non-C-loop domains: 3 in the membrane-spanning domain (T312I, G168R, and S225L) and 1 in the C terminus (R555C). The mutations chosen included the most common mutations in the LQT1 registry. WT and mutant KCNQ1 subunit cDNA and KCNE1 subunit cDNA were transfected into HEK293T cells. 10 Mutant KCNQ1 cDNA was transfected in combination with WT-KCNQ1 to mimic the heterozygous nature of the disease (WT-KCNQ1:mutant KCNQ1:KCNE1ϭ0.5:0.5:1). Fluorescence-conjugated and -tagged constructs were used to evaluate the efficiency of the cotransfection of WT and mutant subunits 11 (see the online-only Data Supplement). Of the HEK293T cells cotransfected with both WT and mutant subunits, 85% to 90% showed fluorescence of at least 1 subunit transfected, and 85% to 95% of transfected cells expressed all the subunits transfected ( Figure I in the online-only Data Supplement). All electrophysiology determinations were performed with the untagged subunit. Expression of WT and mutant subunits was confirmed by Western blot ( Figure II in the online-only Data Supplement). Expression levels were not significantly decreased for the mutant subunits compared with WT. We measured ion channel currents after channel depolarization to 20 mV for 4 seconds from Ϫ80-mV holding potential before and after application of forskolin, a PKA activator (10 mol/mL), with standard electrophysiological techniques and physiological solutions. Current was normalized for all voltages to cell capacitance, and further normalization was performed between WT and mutant. The normalization to WT currents was accomplished by use of WT cell currents transfected and measured on the same day as the currents measured from mutant channel. 10 Pipettes used had resistances ranging from 2 to 6 MOhm. Series resistance compensation of Ͼ70% was used to compensate for voltage drops in the pipette. All experiments were performed at room temperature. Details of the molecular biology and electrophysiological methods are given in the Materials and Methods section of the online-only Data Supplement.
End Point
The primary end point of the study was the occurrence of a first life-threatening cardiac event, comprising ACA requiring external defibrillation as part of the resuscitation or LQTS-related SCD (abrupt in onset without evident cause if witnessed or death that was not explained by any other cause if it occurred in an unwitnessed setting) from birth through 40 years of age. Follow-up after 40 years of age was not included to minimize the influence of coronary disease on cardiac events. The consistency of the results among patients who received an implantable cardioverter-defibrillator during follow-up was evaluated in a secondary analysis that included the occurrence of a first appropriate implantable cardioverterdefibrillator shock in the composite ACA or SCD end point.
Statistical Analysis
Characteristics of the 4 subgroups of patients categorized by mutation location and type were compared by use of a 1-way ANOVA test or 2 and Fisher exact tests as appropriate. The probability of a first life-threatening cardiac event by the mutation location and type subgroup was graphically displayed according to the Kaplan-Meier method, with comparison of instantaneous risk by the log-rank test. The Cox proportional-hazards survivorship model was used to evaluate the independent contribution of clinical and genetic factors to the first occurrence of a life-threatening cardiac event from birth through 40 years of age. The Cox regression models, stratified by decade of birth year and allowing for time-dependent covariates, were fit to estimate the adjusted hazard ratio function of age. Therefore, to fulfill the assumption of proportional hazards for sex over the entire age range, a time-dependent covariate for sex (via an interaction with time) was incorporated, allowing for different hazard ratios by sex before and after 13 years of age. This was justified by the known higher risk of cardiac events or lifethreatening cardiac events among male subjects before adolescence and a similar or higher female risk after the onset of adolescence. [12] [13] [14] [15] [16] Patients who did not have an ECG for QTc measurement (nϭ127) were identified in the Cox models as QTc missing, and all Cox models were adjusted for this QTc-missing parameter. The influence of time-dependent ␤-blocker therapy (the age at which ␤-blocker therapy was initiated) on outcome in the subgroups of patients with and without C-loop missense mutations was determined by adding a time-dependent ␤-blockerby-mutation category interaction term to the multivariable Cox model. We have adjusted for the effect of potential lack of independence between subjects using the robust sandwich estimator for family membership. 17, 18 This robust sandwich covariance estimator is used with correlated data. Correlations among data points in the Cox model lead to underestimation of the SE used in significance testing, whereas the robust estimator uses an inflated variance estimate, taking family membership or other clustering connection into account. All significant predictors of life-threatening event risk remained significant with or without the use of this robust measure of variance. It should be noted that there is seldom more than a single observed outcome (ACA/ SCD) per family (only 7% of families had Ͼ1 event); thus, the standard model-based SEs, confidence intervals, P values, and likelihood ratio tests are valid. 16 We have carried out the following additional secondary analyses: (1) including the biophysical function of the mutations (categorized as dominant negative, haploinsufficiency, and unknown) as a covariate in the model, (2) excluding the large subgroup of patients with V254M mutations, and (3) including appropriate implantable cardioverter-defibrillator shocks in the composite end point. In addition, to assess whether fuller adjustment for family membership was important, regression models that included shared frailty terms (ie, random effects) for family were fit.
The statistical software used for the analyses was SAS version 9.20 (SAS Institute Inc, Cary, NC). For the fitting of models with frailty terms, the software used was Splus 7.0.0 for Sun SPARC. For electrophysiology and biochemistry experiments, 1-way ANOVA followed by the Tukey post hoc test was applied to assess statistical significance for multiple-group comparisons by use of SPSS Statistics (IBM). An unpaired Student t test was used for 2-group comparisons. A 2-sided significance level of 0.05 was used for hypothesis testing.
Results
Study Sample
The spectrum of mutations as categorized by location and type and their respective number of carriers are presented in Table I -A in the online-only Data Supplement. The location and frequency of missense mutations are presented diagrammatically in Figure 1 . Of the 99 total different KCNQ1 mutations identified, 77 were missense mutations and 22 were nonmissense mutations. Missense mutations were further categorized according to their location: 28 different mutations in C-terminus or N-terminus regions (26 in C terminus), 34 mutations in membrane-spanning regions, and 15 mutations in the C-loop regions (8 in S2-S3 loop and 7 in S4-S5 loop). The clinical characteristics of patients in the 4 mutation location/type subgroups are presented in Table 1 . Of the 860 study subjects, 20% had C/N terminal missense mutations, 44% had membrane-spanning missense mutations, 15% had C-loop missense mutations, and 22% had nonmissense mutations. Patients with C-loop missense mutations exhibited the longest QTc interval at enrollment, were treated with ␤-blockers more frequently during follow-up, and had a higher frequency of cardiac events of any type, including syncope, ACA, and LQTS death, compared with the other mutation subgroups. The clinical characteristics of probands only are presented in Table I 
Clinical Outcome of Patients According to Mutation Location and Type
There were 105 first life-threatening cardiac events (27 first ACA events and 78 first LQTS-related SCD events) among the 860 study patients. Patients were enrolled in the registry between 1978 and 2007 with follow-up through 2008; the last reported life-threatening cardiac event occurred in 2005. Figure 2 presents the cumulative probabilities of first lifethreatening cardiac events in the 4 subgroups. There was a significantly higher event rate in the C-loop missense subgroup compared with the other 3 subgroups (log-rank PϽ0.001). Thus, at 40 years of age, the rate of lifethreatening cardiac events was 33% in patients with C-loop missense mutations compared with Յ16% in patients with other mutations.
The findings from the multivariable analysis for the end point of a first life-threatening cardiac event are shown in Table 2 . Notably, the adjusted hazard ratio for C-loop missense versus nonmissense mutation was 2.75 (Pϭ0.009), and there was no statistically significant difference in the risk among the other mutation location/type subgroups.
Secondary confirmatory analyses ( Table II in the onlineonly Data Supplement) showed that patients with C-loop missense mutations had an adjusted hazard ratio of 2.74 (95% confidence interval, 1.68 -4.46; PϽ0.001) for lifethreatening events compared with patients with other mutations. The results were consistent when the biophysical function of the mutations was added as a covariate to the multivariable model. To show that our results do not depend on the C-loop V254M mutation, which is the most common mutation in the C-loop subgroup ( have carried out an additional separate analysis excluding patients who carried this mutation. Results were consistent, with patients with C-loop mutations having a greater risk for life-threatening events, demonstrating that our findings were independent of this mutation. The results were also consistent after inclusion of appropriate implantable cardioverterdefibrillator shocks in the composite end point (adjusted hazard ratio for C-loop missense mutations versus nonmissense mutations. 2.64; 95% confidence interval, 1.64 -4.23; PϽ0.001) and after stratifying patients by enrolling center. To assess whether fuller adjustment for family membership was important, regression models that included frailty terms (ie, random effects) for family were fit in the multivariable Cox models. Models with gamma and gaussian frailty terms were fit, and the C-loop term had a consistent effect size with the original models while remaining statistically significant. Furthermore, in both of these models, the frailty terms were nonsignificant. The consistency of the results provides further support for the higher risk associated with C-loop mutations.
␤-Blocker Therapy
In the present study, the effect of ␤-blocker therapy on the risk of life-threatening events among the different mutation subgroups was assessed as a time-dependent covariate (ie, ␤-blockers were given to patients at different time points during follow-up, and this information was taken into account in the multivariable models). Multivariable analysis showed a significant differential effect of ␤-blocker therapy on the outcome of patients with C-loop missense mutations compared with those who had other mutations (Table 3) . ␤-Blocker therapy was associated with a significant 88% reduction (Pϭ0.02) in the risk of life-threatening events among patients with C-loop missense mutations, whereas the benefit of ␤-blocker therapy was significantly attenuated among patients with other mutations in the KCNQ1 channel (adjusted hazard ratio, 0.82; Pϭ0.68; P for treatment-bymutation location/type interactionϭ0.04).
Consistent with those findings, the rate of ACA or SCD ( Figure 3 ) was lowest among patients with C-loop missense mutations who were treated with ␤-blockers and highest among patients with C-loop missense mutations who were not treated with ␤-blockers (0.17 versus 1.11 per 100 patientyears, respectively), whereas patients with other mutations in the KCNQ1 channel exhibited intermediate and similar rates of life-threatening events with and without ␤-blocker therapy (0.36 and 0.38 per 100 patient-years, respectively; Figure 3 ).
In addition, we have repeated analysis for only patients who were treated by ␤-blockers (at any point in time) and consistently found that there is differential response to ␤-blocker therapy depending on mutation location (␤-blocker versus no ␤-blocker therapy in patients with C-loop mutations: hazard ratio, 0.15; 95% confidence interval, 0.01-1.73; Pϭ0.13; ␤-blocker versus no ␤-blocker therapy in patients with non-C-loop mutations: hazard ratio, 1.89; 95% confidence interval, 0.54 -6.63; Pϭ0.32) with a value for treatment-by-mutation location/type interaction of Pϭ0.028. To understand the mechanism underlying the increase in risk associated with C-loop mutations, we measured channel basal function and regulation in 8 mutant channels associated with LQT1: 3 in the membrane-spanning domains (T312I, G168R, and S225L), 4 located in C loops (G189R, R190Q, R243C, and V254M), and 1 in the C terminus (R555C; Figure 4A ). WT and mutant subunits were coexpressed for all experiments. Basal channel current was decreased for all mutations studied compared with WT subunits ( Figure 4B ). In addition, because activation by PKA is thought to be particularly important for I Ks function and to underlie arrhythmogenesis in LQT1, 4, 19, 20 we measured the effect of the PKA activator forskolin. All C-loop mutations tested showed dramatically impaired response to forskolin, whereas the other mutations showed a strong activation by forskolin, as did the WT KCNQ1 channel ( Figure 4C and 4D ).
Discussion
The present analysis of 860 LQT1 patients with a wide range of mutations in the KCNQ1 channel provides several impor-tant implications regarding risk assessment and management in this study sample. First, patients with missense mutations located in the C loops exhibit the highest risk for lifethreatening cardiac events independently of clinical and ECG variables. Second, ␤-blocker therapy is associated with a pronounced reduction in the risk of ACA or SCD among carriers of missense mutations in the C loop, whereas the benefit of this mode of medical therapy is significantly attenuated in LQT1 patients with other mutations. Third, expression studies of C-loop mutations suggest that an impaired regulation by PKA is the mechanism underlying the increased risk for cardiac events independently of patient QTc and may explain the pronounced response to medical therapy with ␤-blockers among patients with C-loop mutation carriers.
We have recently shown that patients with mutations located in the transmembrane region have a significantly higher rate of cardiac events than those with mutations located in the C terminus. 8 In addition, mutations in the transmembrane domain were suggested to be associated with . Regulation of LQT1 mutant channels by protein kinase A. A, Schematic representation of location of the mutations used in the study. B, Effect of each of the mutations studied in basal nonstimulated cell currents. Average current measured for cells expressing wild-type (WT) and mutant subunits measured at 40 mV after 3 seconds of depolarization. KCNQ1 and KCNE1 subunit were expressed at a ratio of 0.5 WT-KCNQ1:0.5 KCNQ1 mutant:1 KCNE1 or 0.5 WT-KCNQ1:0.5 vector:1 KCNE1 for T haploinsufficient channels. *PϽ0.05 vs WT. C, Top, Typical ion channel current measured before and after 10 minutes of application of the protein kinase A activator forskolin (FK; 10 mol/L) for WT and WT and mutant subunits coexpressed. Scale bars in each panel are 10 pA/pF and 2 seconds. Scale bars are the same for all constructs. Bottom, Time course of current regulation by forskolin measured at 20 mV after 3 seconds of depolarization for channels formed by either WT or mutant coexpressed with WT subunits as indicated. Current was normalized to current in the absence of forskolin application. KCNQ1 and KCNE1 subunits were expressed at a ratio of 0.5 WT-KCNQ1:0.5 KCNQ1 mutant:1 KCNE1 or 1 WT-KCNQ1:1 KCNE1 for WT channels. Currents were activated by 4-second depolarizing steps to 20 mV from a Ϫ80-mV holding potential. These were followed by a step to Ϫ20 mV. D, Summary data for experiments done as in C. *PϽ0.05 vs the current before stimulation (black bar) in each group. a greater prolongation of the QTc during exercise. 21 The present findings confirm previous work indicating that mutations in the transmembrane region are associated with higher risk but suggest that within the transmembrane region there are distinct functional domains, with the C loops (but not in the membrane-spanning domain) being associated with increased risk for life-threatening cardiac events compared with other mutations in the KCNQ1 channel. The S2-S3 and S4-S5 C loops have previously been suggested to have an important functional role in modifying the function of voltage-gated potassium channels. 22 In particular for I Ks , the S4-S5 loop has been suggested to mediate a functional interaction with the auxiliary KCNE1 subunits. 23 Most recently, LQT1 mutations in C loops, when expressed in the absence of WT subunits, were suggested to affect adrenergic channel regulation. 9 Our results showed that even when expressed in the presence of WT subunits, C-loop mutations can dramatically affect channel regulation. Consistent with our results, induced pluripotent stem cells differentiated into cardiomyocytes from a patient carrying R190Q were recently shown to lack adrenergic regulation of their I Ks current. 24 Also consistent with our results, for haploinsufficient mutations, not tested here, a simple lack of mutant subunit expression is expected to maintain normal adrenergic regulation, contributing to the milder phenotype of these mutations. 8 It is conceivable that a decrease in channel regulation, as observed for the C-loop mutations, will lead to an increase in the burden of the mutation during adrenergic stimulus. The increase in cardiac risk associated with C-loop mutations is independent of traditional clinical variables; this can be explained by a blunted PKA-mediated activation because QTc is generally measured at rest. Thus, our results suggest that exercise may exacerbate the QTc prolongation for C-loop mutants. It has recently been suggested that the mutation KNCQ1(A341V) also caused an impairment in ␤-adrenergic activation. 25 This mutation is located at the end of the S6 domain, a region suggested to interact with the S4-S5 loop. 26 It is possible that other mutations causing functional impairment similar to that of the C-loop mutations may also carry the increased cardiac risk and ␤-blocker efficacy.
Current guidelines recommend empirical therapy with ␤-blockers in all LQTS patients. 27 The present study shows, for the first time, a mutation-specific response to ␤-blocker therapy in LQT1, demonstrating that ␤-blockers were associated with a significantly greater reduction in the risk of life-threatening cardiac events among patients with mutations located in the C loops compared with all other mutations. It is conceivable that during ␤-adrenergic stimulation, patients with mutations located in the C loops have an unopposed increase in inward Ca 2ϩ currents and prolongation of repolarization caused by blunted PKA-mediated activation of I Ks . 5 ␤-Blockers may decrease these unopposed inward Ca 2ϩ currents, shorten repolarization, and reduce the risk of ventricular arrhythmias, 28 whereas patients with other mutations do not exhibit such an effect.
Study Limitations
Clinical history was obtained on enrollment in the registry, so follow-up data in the current study comprised historical data from birth to enrollment and prospective information collected at yearly intervals after enrollment.
The International LQTS Registry records therapies that are prescribed at the discretion of the treating physicians to enrolled subjects; therefore, ␤-blocker administration was not randomized. However, because the patient's physician would have been blinded to whether the patient had a C-loop mutation, the interaction of this with ␤-blocker therapy is still compelling. Prior studies from the International LQTS Registry have shown that ␤-blocker therapy is associated with a significant reduction in the risk of cardiac events in LQTS patients. However, the present study is the first to assess the benefit of ␤-blocker therapy for the reduction in the risk of ACA or SCD among LQT1 patients. We have shown that ␤-blocker therapy is associated with a significant 88% (Pϭ0.02) reduction in the risk of life-threatening cardiac events among LQT1 carriers of the higher-risk C-loop mutations. Risk reduction associated with ␤-blocker therapy in the total study sample and among carriers of the low-risk non-C-loop mutations did not reach statistical significance. The lack of a significant ␤-blocker effect may be due to sample size limitation and a more limited number of events among carriers of lower risk mutations. Thus, lower-risk patients should still be treated with ␤-blocker therapy according to guidelines 27 because the cumulative probability of ACA or SCD from birth through 40 years of age among patients with non-C-loop missense mutations was still considerable (between 11% and 16%). These limitations also suggest that further studies in independent populations are needed before the results can be extrapolated to clinical practice.
The present results, derived from LQTS families enrolled in the registry, may be confounded by familial factors such as ethnicity. To minimize bias, we adjusted for family membership in the multivariable models and carried out a secondary analysis in which additional adjustment was made for proband status. These analyses yielded similar results, further supporting the consistency of our findings. Of the 127 LQT1 mutation carriers without available ECG data, 58 (46%) died suddenly at a young age without a documented ECG. To minimize this bias related to exclusion of higher-risk patients, all multivariable analyses included adjustment for a QTcmissing category in addition to the category of QTc Ͼ500 milliseconds.
Channel current and response to forskolin were analyzed for 8 mutations of 99 mutation types observed in this study, but the robust findings in these expression studies strongly support our suggested mechanism. Experimental data were performed at room temperature; results may be different at physiological temperature.
Conclusions
We used a combination of clinical analysis and cellular electrophysiology experiments to investigate the molecular determinants and mechanisms underlying the clinical outcomes of a large cohort of subjects having a spectrum of KCNQ1 mutations categorized by their code type and location. Patients with KCNQ1 missense mutations located in the cytoplasmic loops had a significantly greater risk for lifethreatening cardiac events and gained grater benefit when treated with ␤-blockers compared with patients having other KCNQ1 missense or nonmissense mutations independently of clinical risk factors. We suggest that a combination of a decrease in basal function and altered adrenergic regulation of the I Ks channel underlies the increased cardiac risk in this subgroup of patients. Our results highlight the importance of understanding the molecular determinants and mechanisms underlying arrhythmogenesis to identify cardiac risk factors for LQT1 patients.
